ADAPTIN BIO, INC. (APTN) SEC Filings

ADAPTIN BIO, INC. (APTN) has filed to register the resale of up to 382,400 shares of common stock held by selling stockholders and up to 38,240 shares issuable upon exercise of placement agent warrants. All resale proceeds go to the selling stockholders; Adaptin would receive cash only if the placement agent warrants are exercised.

The company is an early-stage biotechnology business developing its BRiTE (Brain Bispecific T‑cell Engager) platform to deliver therapeutics across the blood–brain barrier, with lead candidate APTN‑101 targeting EGFRVIII‑positive tumors such as glioblastoma. Common stock trades on the OTCQB under symbol APTN; on August 25, 2026, the last quoted price was $6.27 per share, with 9,244,937 shares outstanding.

Adaptin has generated no commercial revenue, has incurred recurring losses and negative operating cash flows, and its independent auditor has expressed substantial doubt about its ability to continue as a going concern. Management expects to require substantial additional capital, including in 2026, to fund clinical development and potential commercialization, and discloses extensive business, regulatory, manufacturing, financing and reimbursement risks associated with its drug-development programs.

Adaptin Bio, Inc. (APTN) filed a prospectus supplement covering the resale of 1,901,482 shares of common stock and 2,233,083 shares of common stock underlying warrants, all held by selling stockholders. The supplement incorporates new information from a Current Report on Form 8-K dated August 20, 2026.

Adaptin announced that enrollment has opened for a first-in-human, open-label, dose-escalation Phase 1 trial of its BRiTE therapeutic APTN-101 for EGFRvIII-positive glioblastoma, conducted with Duke University and expected to enroll up to 15 adult patients. The company highlights preclinical data showing more than 7-fold increased brain distribution and 70%–80% complete tumor eradication in mouse models. Adaptin’s common stock trades on the OTCQB under “APTN” with a last quoted bid price of $6.27 per share on August 24, 2026.

ADAPTIN BIO, INC. (APTN) announced that enrollment has opened for a Phase 1, open-label, dose-escalation clinical trial of its proprietary BRiTE (Brain Bispecific T cell Engager) therapeutic APTN-101 as a treatment for EGFRvIII-positive glioblastoma, in collaboration with Duke University.

The study will enroll up to 15 adult patients with World Health Organization Grade IV Malignant Glioma. The primary objective is to evaluate the safety profile and maximum tolerated dose, with the primary endpoint being the proportion of patients with a dose limiting toxicity at each dose level. Secondary endpoints include pharmacokinetics and objective response rate, and exploratory endpoints include cytokine changes, anti-BRiTE antibodies, overall survival and progression free survival.

In preclinical models, APTN-101 increased brain distribution of an EGFRvIII T-cell engager by more than 7-fold and completely eradicated EGFRvIII glioblastoma tumors in 70%–80% of mice, while showing an excellent safety profile. The company highlights the significant unmet need in glioblastoma, where median survival is 12–18 months and about 5% of patients survive beyond five years.

Adaptin Bio, Inc. (APTN) filed a prospectus supplement for the resale of 1,901,482 shares of common stock by selling stockholders and 2,233,083 shares of common stock underlying warrants held by those stockholders. The supplement incorporates Adaptin’s Quarterly Report for the period ended June 30, 2026.

Adaptin is a preclinical-stage biopharmaceutical company developing its BRiTE platform and lead bispecific T‑cell engager APTN‑101 for glioblastoma and other CNS tumors. For the six months ended June 30, 2026, it reported a net loss of $2,351,408, with an accumulated deficit of $11,643,209 and cash and cash equivalents of $670,488.

Management states these conditions, together with expected ongoing operating losses, raise substantial doubt about Adaptin’s ability to continue as a going concern. The company is funding operations through private placements and warrant exercises and completed multiple 2026 closings under a follow‑on offering at $5.00 per share. Material weaknesses in internal control over financial reporting remain unresolved as of June 30, 2026. As of August 11, 2026, there were 9,233,573 shares of common stock outstanding.

Adaptin Bio, Inc. reports continued operating losses and tight liquidity for the quarter ended June 30, 2026. The company, which is developing its BRiTE platform and lead bispecific T‑cell engager APTN‑101 for brain cancers, recorded a three‑month net loss of $1.21 million and a six‑month net loss of $2.35 million, with an accumulated deficit of $11.64 million.

Operating expenses for the quarter fell 21% year over year to $1.20 million, driven largely by a 59% reduction in research and development as several preclinical programs and a tox study wound down, partially offset by higher stock‑based compensation and personnel costs. Net cash used in operating activities for the first half of 2026 declined 68% to $1.05 million.

Adaptin ended June 30, 2026 with $670,488 in cash and cash equivalents and a stockholders’ deficit of $1.67 million. Management states that these levels, together with planned development spending and a working capital deficit, create substantial doubt about the company’s ability to continue as a going concern without additional financing. The company raised $912,000 in follow‑on private placements and $669,106 net from warrant exercises during the first half, and reports outstanding equity‑classified warrants for 2,461,381 shares. Internal control weaknesses around non‑routine transactions, R&D accruals, and income tax accounting remain unresolved.

Adaptin Bio, Inc., an emerging growth biopharmaceutical company focused on delivering therapeutics across the blood-brain barrier for brain cancers and other CNS and systemic diseases, has filed a post-effective amendment to its Form S-1 for a continuous Rule 415 offering. The amendment updates the prospectus for the resale of up to 1,901,482 outstanding shares of common stock by selling stockholders and the company’s potential issuance of up to 2,233,083 additional shares upon exercise of outstanding A, B and Pre-Merger warrants. Adaptin’s common stock trades on the OTCQB under “APTN,” with a last quoted price of $6.25 per share on July 14, 2026, and there were 9,079,416 shares outstanding as of July 16, 2026.

The company will not receive proceeds from share resales but would receive cash only upon warrant exercises. The registered securities represent a potential sale of 4,134,565 shares, about 31.8% of fully diluted shares, which the company states could pressure liquidity and trading prices. Officers and directors are subject to a two-year lock-up from first OTC or exchange trading. Adaptin remains pre-revenue, with its lead candidate APTN-101 entering first-in-human brain cancer studies, and its auditor has expressed substantial doubt about its ability to continue as a going concern. The company discloses that significant additional capital will be needed by or before 2026 to fund clinical development and that failure to raise funds could force it to scale back programs, pursue dilutive financings or consider liquidation.

Adaptin Bio, Inc. files a prospectus supplement to register the resale of 1,901,482 shares of common stock and 2,233,083 shares underlying warrants held by selling stockholders, as part of its Form S-1 shelf.

The supplement attaches Amendment No. 1 to the Company’s Form 10-K for the fiscal year ended December 31, 2025, which updates Item 15(b) and Exhibit 23.1 to add an updated auditor consent. The auditor's consent includes an explanatory paragraph stating substantial doubt about the Company’s ability to continue as a going concern.

Shares outstanding were 8,903,229 as of June 11, 2026, and the last quoted OTCQB price was $6.18 per share on June 9, 2026. The registration covers resale by selling holders; proceeds treatment is identified as resale by holders.